What this means
The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Active not recruiting
- Who can join
- Ages 40 and over
- Where
- 4 sites
The science
- Registered title
- Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older
- Trial ID
- NCT06447779 ↗
- Phase
- PHASE 3
- Study type
- interventional
- Conditions
- Herpes Zoster
- What is tested
- Recombinant Zoster Vaccine (CHO Cell), NaCl solution Placebo
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
- Ages
- 40 Years to no maximum
- Dates
- First posted Jun 7, 2024 · updated Oct 19, 2026
Registry summary
The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.
Sites (4)
- Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China
- Henan Center for Diseases Control and Prevention, Zhengzhou, Henan, China
- Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China
- Yunnan Center For Disease Control and Prevention, Kunming, Yunnan, China